Citations (57)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Jeverson Moreira & Pierre Alexis Geoffroy. (2016) Lithium and bipolar disorder: Impacts from molecular to behavioural circadian rhythms. Chronobiology International 33:4, pages 351-373.
Read now
Read now
Frank Bellivier, Pierre-Alexis Geoffroy, Bruno Etain & Jan Scott. (2015) Sleep- and circadian rhythm–associated pathways as therapeutic targets in bipolar disorder. Expert Opinion on Therapeutic Targets 19:6, pages 747-763.
Read now
Read now
Falk W Lohoff & Thomas N Ferraro. (2010) Pharmacogenetic considerations in the treatment of psychiatric disorders. Expert Opinion on Pharmacotherapy 11:3, pages 423-439.
Read now
Read now
Martin Alda, Tomas Hajek, Cynthia Calkin & Claire O'Donovan. (2009) Treatment of bipolar disorder: New perspectives. Annals of Medicine 41:3, pages 186-196.
Read now
Read now
Articles from other publishers (53)
Claudia Pisanu, Anna Meloni, Giovanni Severino & Alessio Squassina. (2022) Genetic and Epigenetic Markers of Lithium Response. International Journal of Molecular Sciences 23:3, pages 1555.
Crossref
Crossref
Claudia Pisanu & Alessio Squassina. 2022. Psychiatric Genomics. Psychiatric Genomics
203
222
.
Fanny Senner, Mojtaba Oraki Kohshour, Safa Abdalla, Sergi Papiol & Thomas G. Schulze. (2021) The Genetics of Response to and Side Effects of Lithium Treatment in Bipolar Disorder: Future Research Perspectives. Frontiers in Pharmacology 12.
Crossref
Crossref
Claudia Pisanu & Alessio Squassina. 2021. Neurobiology of Bipolar Disorder. Neurobiology of Bipolar Disorder
135
142
.
Alfredo B. Cuéllar-Barboza, Susan L. McElroy, Marin Veldic, Balwinder Singh, Simon Kung, Francisco Romo-Nava, Nicolas A. Nunez, Alejandra Cabello-Arreola, Brandon J. Coombes, Miguel Prieto, Hannah K. Betcher, Katherine M. Moore, Stacey J. Winham, Joanna M. Biernacka & Mark A. Frye. (2020) Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection. International Journal of Bipolar Disorders 8:1.
Crossref
Crossref
Maciej D. Sobczak & Joanna M. Pawlak. (2020) Lithium pharmacogenetics. Two decades of studies. Pharmacotherapy in Psychiatry and Neurology 36:1, pages 67-82.
Crossref
Crossref
Estela Salagre, Eduard Vieta & Iria Grande. 2020. Personalized Psychiatry. Personalized Psychiatry
423
436
.
Claudia Pisanu, Alessio Squassina, Martin Alda & Giovanni Severino. 2020. Personalized Psychiatry. Personalized Psychiatry
393
402
.
Shani Stern, Sara Linker, Krishna C. Vadodaria, Maria C. Marchetto & Fred H. Gage. (2019) Prediction of Response to Drug Therapy in Psychiatric Disorders. FOCUS 17:3, pages 294-307.
Crossref
Crossref
Simone Pisano, Marco Pozzi, Gennaro Catone, Giulia Scrinzi, Emilio Clementi, Giangennaro Coppola, Annarita Milone, Carmela Bravaccio, Paramala Santosh & Gabriele Masi. (2019) Putative Mechanisms of Action and Clinical Use of Lithium in Children and Adolescents: A Critical Review. Current Neuropharmacology 17:4, pages 318-341.
Crossref
Crossref
Eduard Maron, Chen-Chia Lan & David Nutt. 2019. Treatment Resistance in Psychiatry. Treatment Resistance in Psychiatry
33
63
.
Bharathram Sathur Raghuraman, Pradip Paul, Ravi Kumar Nadella, Vaisnvy Kapur, Meera Purushottam, Sanjeev Jain, Ramakrishnan Kannan, Maria Del Zompo & Biju Viswanath. (2018) GSK-3b 50 T/C polymorphism in bipolar disorder and its relationship with clinical phenotypes and treatment response. Journal of Affective Disorders 241, pages 433-435.
Crossref
Crossref
Claudia Pisanu, Urs Heilbronner & Alessio Squassina. (2018) The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine. Molecular Diagnosis & Therapy 22:4, pages 409-420.
Crossref
Crossref
Shani Stern, Sara Linker, Krishna C. Vadodaria, Maria C. Marchetto & Fred H. Gage. (2018) Prediction of response to drug therapy in psychiatric disorders. Open Biology 8:5, pages 180031.
Crossref
Crossref
Beatriz Mata Saenz, Laura Nuevo Fernández, Leonor Asensio Aguerri, Erica López Lavela, Fernando García Lázaro & Irene Díaz Quero. (2017) Revisión sistemática de la evidencia de existencia de marcadores genéticos en la respuesta al litio en pacientes con trastorno bipolar tipo i. Psiquiatría Biológica 24:3, pages 106-112.
Crossref
Crossref
M. Budde, D. Degner, J. Brockmöller & T.G. Schulze. (2017) Pharmacogenomic aspects of bipolar disorder: An update. European Neuropsychopharmacology 27:6, pages 599-609.
Crossref
Crossref
Alexandre Dayer, Nader Perroud & Jean-Michel Aubry. 2017. The Science and Practice of Lithium Therapy. The Science and Practice of Lithium Therapy
141
155
.
Pierre Alexis Geoffroy & Bruno Etain. 2017. The Science and Practice of Lithium Therapy. The Science and Practice of Lithium Therapy
111
124
.
Janusz K. Rybakowski. 2016. Genetic Influences on Response to Drug Treatment for Major Psychiatric Disorders. Genetic Influences on Response to Drug Treatment for Major Psychiatric Disorders
93
109
.
Marina Mitjans, Bárbara Arias, Esther Jiménez, Jose M. Goikolea, Pilar A. Sáiz, M. Paz García-Portilla, Patricia Burón, Julio Bobes, Eduard Vieta & Antoni Benabarre. (2015) Exploring Genetic Variability at PI, GSK3, HPA, and Glutamatergic Pathways in Lithium Response. Journal of Clinical Psychopharmacology 35:5, pages 600-604.
Crossref
Crossref
T. Abreu & M. Bragança. (2015) The bipolarity of light and dark: A review on Bipolar Disorder and circadian cycles. Journal of Affective Disorders 185, pages 219-229.
Crossref
Crossref
Eleonore Beurel, Steven F. Grieco & Richard S. Jope. (2015) Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases. Pharmacology & Therapeutics 148, pages 114-131.
Crossref
Crossref
Naji C Salloum, Michael J McCarthy, Susan G Leckband & John R Kelsoe. (2014) Towards the clinical implementation of pharmacogenetics in bipolar disorder. BMC Medicine 12:1.
Crossref
Crossref
Guodi Chen, Jun Tang, Guangwei Yu, Yiping Chen, Liancong Wang & Yao Zhang. (2014) Meta-analysis demonstrates lack of association of the GSK3B −50C/T polymorphism with risk of bipolar disorder. Molecular Biology Reports 41:9, pages 5711-5718.
Crossref
Crossref
Adem Can, Thomas G. Schulze & Todd D. Gould. (2014) Molecular actions and clinical pharmacogenetics of lithium therapy. Pharmacology Biochemistry and Behavior 123, pages 3-16.
Crossref
Crossref
Janusz K. Rybakowski. (2014) Response to Lithium in Bipolar Disorder: Clinical and Genetic Findings. ACS Chemical Neuroscience 5:6, pages 413-421.
Crossref
Crossref
Janusz K Rybakowski, Monika Dmitrzak-Weglarz, Sebastian Kliwicki & Joanna Hauser. (2014) Polymorphism of circadian clock genes and prophylactic lithium response. Bipolar Disorders 16:2, pages 151-158.
Crossref
Crossref
Janusz K Rybakowski, Maria Abramowicz, Aleksandra Szczepankiewicz, Michal Michalak, Joanna Hauser & Stanislaw Czekalski. (2013) The association of glycogen synthase kinase-3beta (GSK-3β) gene polymorphism with kidney function in long-term lithium-treated bipolar patients. International Journal of Bipolar Disorders 1:1.
Crossref
Crossref
J. D. Gray & B. S. McEwen. (2013) Lithium's role in neural plasticity and its implications for mood disorders. Acta Psychiatrica Scandinavica 128:5, pages 347-361.
Crossref
Crossref
M J McCarthy, H Wei, Z Marnoy, R M Darvish, D L McPhie, B M Cohen & D K Welsh. (2013) Genetic and clinical factors predict lithium’s effects on PER2 gene expression rhythms in cells from bipolar disorder patients. Translational Psychiatry 3:10, pages e318-e318.
Crossref
Crossref
Yen-Feng Lin, Ming-Chyi Huang & Hsing-Cheng Liu. (2013) Glycogen synthase kinase 3β gene polymorphisms may be associated with bipolar I disorder and the therapeutic response to lithium. Journal of Affective Disorders 147:1-3, pages 401-406.
Crossref
Crossref
Giovanni Severino, Alessio SquassinaMarta Costa, Claudia Pisanu, Stefano Calza, Martin Alda, Maria Del Zompo & Mirko Manchia. (2013) Pharmacogenomics of bipolar disorder. Pharmacogenomics 14:6, pages 655-674.
Crossref
Crossref
Janusz K. Rybakowski. (2013) Genetic Influences on Response to Mood Stabilizers in Bipolar Disorder. CNS Drugs 27:3, pages 165-173.
Crossref
Crossref
Janusz K Rybakowski, Piotr Czerski, Monika Dmitrzak-Weglarz, Sebastian Kliwicki, Anna Leszczynska-Rodziewicz, Agnieszka Permoda-Osip, Maria Skibinska, Aleksandra Suwalska, Aleksandra Szczepankiewicz & Joanna Hauser. (2011) Clinical and pathogenic aspects of candidate genes for lithium prophylactic efficacy. Journal of Psychopharmacology 26:3, pages 368-373.
Crossref
Crossref
Falk W. Lohoff. 2012. Principles of Psychiatric Genetics. Principles of Psychiatric Genetics
53
68
.
Oksana Kaidanovich-Beilin & James Robert Woodgett. 2012. Protein Kinase Technologies. Protein Kinase Technologies
153
188
.
Janusz K. Rybakowski, Maria Skibinska, Aleksandra Suwalska, Anna Leszczynska-Rodziewicz, Leszek Kaczmarek & Joanna Hauser. (2011) Functional polymorphism of matrix metalloproteinase-9 (MMP-9) gene and response to lithium prophylaxis in bipolar patients. Human Psychopharmacology: Clinical and Experimental 26:2, pages 168-171.
Crossref
Crossref
Peter P. Zandi & Jennifer T. Judy. (2010) The Promise and Reality of Pharmacogenetics in Psychiatry. Clinics in Laboratory Medicine 30:4, pages 931-974.
Crossref
Crossref
Michael J McCarthy, Susan G Leckband & John R Kelsoe. (2010) Pharmacogenetics of lithium response in bipolar disorder. Pharmacogenomics 11:10, pages 1439-1465.
Crossref
Crossref
Xiaohua Li & Richard S Jope. (2010) Is Glycogen Synthase Kinase-3 a Central Modulator in Mood Regulation?. Neuropsychopharmacology 35:11, pages 2143-2154.
Crossref
Crossref
Ana Andreazza, Jun Feng Wang & Trevor Young. 2010. Bipolar Disorder. Bipolar Disorder
228
243
.
S.D. Patel, H. Le‐Niculescu, D.L. Koller, S.D. Green, D.K. Lahiri, F.J. McMahon, J.I. NurnbergerJrJr & A.B. NiculescuIIIIII. (2010) Coming to grips with complex disorders: Genetic risk prediction in bipolar disorder using panels of genes identified through convergent functional genomics. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 153B:4, pages 850-877.
Crossref
Crossref
Peter P. Zandi & Jennifer T. Judy. (2010) The Promise and Reality of Pharmacogenetics in Psychiatry. Psychiatric Clinics of North America 33:1, pages 181-224.
Crossref
Crossref
Alessio Squassina, Mirko Manchia & Maria Del Zompo. (2010) Pharmacogenomics of Mood Stabilizers in the Treatment of Bipolar
Disorder. Human Genomics and Proteomics 2:1.
Crossref
Crossref
Jeremy W. Gawryluk & L. Trevor Young. 2011. Behavioral Neurobiology of Bipolar Disorder and its Treatment. Behavioral Neurobiology of Bipolar Disorder and its Treatment
139
165
.
Julien Mendlewicz. (2009) Disruption of the Circadian Timing Systems. CNS Drugs 23:Supplement 2, pages 15-26.
Crossref
Crossref
H. Le-Niculescu, S.D. Patel, M. Bhat, R. Kuczenski, S.V. Faraone, M.T. Tsuang, F.J. McMahon, N.J. Schork, J.I. NurnbergerJr.Jr. & A.B. NiculescuIIIIII. (2009) Convergent functional genomics of genome-wide association data for bipolar disorder: Comprehensive identification of candidate genes, pathways and mechanisms. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 150B:2, pages 155-181.
Crossref
Crossref
Jiajun Shi, Jacqueline K. Wittke-Thompson, Judith A. Badner, Eiji Hattori, James B. Potash, Virginia L. Willour, Francis J. McMahon, Elliot S. Gershon & Chunyu Liu. (2008) Clock genes may influence bipolar disorder susceptibility and dysfunctional circadian rhythm. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 147B:7, pages 1047-1055.
Crossref
Crossref
Ana Martinez. (2008) Preclinical efficacy on GSK‐3 inhibitors: Towards a future generation of powerful drugs. Medicinal Research Reviews 28:5, pages 773-796.
Crossref
Crossref
Alessandro Serretti, Francesco Benedetti, Laura Mandelli, Raffaella Calati, Barbara Caneva, Cristina Lorenzi, Valentina Fontana, Cristina Colombo & Enrico Smeraldi. (2008) Association between GSK-3β -50T/C polymorphism and personality and psychotic symptoms in mood disorders. Psychiatry Research 158:2, pages 132-140.
Crossref
Crossref
Mazda Adli, Dorothea L. Hollinde, Thomas Stamm, Katja Wiethoff, Martina Tsahuridu, Julia Kirchheiner, Andreas Heinz & Michael Bauer. (2007) Response to Lithium Augmentation in Depression is Associated with the Glycogen Synthase Kinase 3-Beta −50T/C Single Nucleotide Polymorphism. Biological Psychiatry 62:11, pages 1295-1302.
Crossref
Crossref
Colleen A. McClung. (2007) Circadian genes, rhythms and the biology of mood disorders. Pharmacology & Therapeutics 114:2, pages 222-232.
Crossref
Crossref
Michael K. Rowe, Charlotte Wiest & De-Maw Chuang. (2007) GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neuroscience & Biobehavioral Reviews 31:6, pages 920-931.
Crossref
Crossref